The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11024 malaria professionals are enjoying the free benefits of MalariaWorld today

Sanaria; PfSPZ-CVac; malaria; vaccine; Nature

Sanaria vaccine trial results demonstrate unprecedented progress in worldwide battle against variant malaria parasites

July 1, 2021 - 12:54 -- Sanaria Inc.

Findings published in Nature offer potential for use by travelers and prevention of malaria in African populations in near future

ROCKVILLE, MD, USA – June 30, 2021 – Researchers from Sanaria® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines.

In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.

Subscribe to RSS - Sanaria; PfSPZ-CVac; malaria; vaccine; Nature